Atypical fibroxanthoma (AFX) is a rare and aggressive form of skin cancer that can be difficult to diagnose. It is most commonly found in elderly individuals and can be found in any area of the body. AFX is characterized by a rapidly growing, red-brown to yellow-brown papule or nodule, often with a central ulceration. Despite its rarity, it is important for doctors to be aware of the signs and symptoms of AFX, as early diagnosis and treatment are critical for successful outcomes.
Atypical fibroxanthoma (AFX) is a rare and aggressive form of skin cancer. It is a type of soft-tissue sarcoma, which is a cancer that develops in the connective tissues of the body. AFX is most commonly found in elderly individuals and can be found in any area of the body, although it is most commonly found on the head or neck. It is characterized by a rapidly growing, red-brown to yellow-brown papule or nodule, often with a central ulceration.
The most common sign of AFX is a rapidly growing, red-brown to yellow-brown papule or nodule. This lesion may be tender to the touch and may have a central ulceration. Other signs and symptoms of AFX may include itching, bleeding, and pain. The lesion may also be accompanied by a reddish-brown halo or a crusty, flaky surface.
Diagnosis of AFX begins with a physical examination. During the physical exam, the doctor will examine the lesion and may take a biopsy. A biopsy is a procedure in which a small sample of the lesion is removed and sent to a laboratory for further examination. The laboratory will examine the sample under a microscope and may order additional tests to confirm the diagnosis.
The primary treatment for AFX is surgical excision. This involves surgically removing the lesion and any surrounding tissue. In some cases, radiation therapy may be used to reduce the size of the lesion prior to surgery. In cases where the lesion is too large to be removed surgically, chemotherapy may be used to shrink the tumor.
Unfortunately, there is no known way to prevent AFX. However, it is important to practice sun safety and to avoid prolonged exposure to ultraviolet (UV) radiation. This includes wearing sunscreen and protective clothing when outdoors, avoiding tanning beds, and avoiding direct sun exposure during peak UV hours. Additionally, it is important to monitor any changes in the skin and to seek medical attention if any suspicious lesions are found.
Atypical fibroxanthoma (AFX) is a rare and aggressive form of skin cancer that can be difficult to diagnose. It is most commonly found in elderly individuals and can be found in any area of the body. AFX is characterized by a rapidly growing, red-brown to yellow-brown papule or nodule, often with a central ulceration. Early diagnosis and treatment are critical for successful outcomes, so it is important for doctors to be aware of the signs and symptoms of AFX. While there is no known way to prevent AFX, it is important to practice sun safety and to monitor any changes in the skin.
1.
Canine Cancer Vaccine: A Potential Resurrection? U.S. KK. Snubs Enertu.
2.
An Intimate Life of Medical Innovation and Charity.
3.
Decoding calcifications in breast cancer: Towards personalized medicine
4.
Could CT scans be fueling a future rise in cancer cases, as a new study suggests?
5.
Study: Pre-operative THP leads to pCR in 64% of early-stage HER2+ ER- breast cancer patients
1.
All You Need To Know About Cancer Antigen 27-29: Causes, Symptoms & Treatment
2.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
3.
Expanding Oncology Frontiers: Rare Cancers, Breakthroughs, and Precision Medicine Advances
4.
Revolutionizing Lung Cancer Treatment: Exploring the Benefits of Wedge Resection Surgery
5.
From Autoimmune Disorders to COVID-19: How Plasmapheresis Is Revolutionizing Modern Medicine
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation